Assembly Biosciences, Inc. exercised its profit-share option with Gilead Sciences, sharing 40% of U.S. development costs and profits for its helicase-primase inhibitor program.
Public source
Publisher name
Public post
NEWS: Today we announced we’ve exercised our profit-share option with Gilead Sciences, sharing 40% of U.S. development costs and profits for our helicase-primase inhibit…
Company
Assembly Biosciences, Inc.
Passionate about making a profound impact on patients’ lives
- Industry
- Biotechnology Research
- Location
- South San Francisco, US
- Company size
- 51–200 employees
About Assembly Biosciences, Inc.
Assembly Biosciences is a biotechnology company dedicated to the development of innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. For more information, visit assemblybio.com. Assembly is headquartered in South San Francisco.
See moreDiscover more
Similar signals
Similar public activity from other companies.
Capital & Finance
Gossamer Bio
Gossamer Bio announced up to $250 million in financing to support the program through potential FDA approval.
Capital & Finance
Scribe Therapeutics
Scribe Therapeutics completed its initial public offering in the first half of 2029.
Capital & Finance
BlossomHill Therapeutics, Inc.
BlossomHill Therapeutics, Inc. was listed on the Nasdaq Exchange.
Capital & Finance
Kazia Therapeutics Limited
Kazia Therapeutics Limited announced the oversubscribed closing of a public offering of up to $120 million, generating approximately $40 million in upfront gross proceeds.
Capital & Finance
Armata Pharmaceuticals, Inc.